

30 December 2024

Privatisation by way of merger

Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc.

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

| Party | Date | Description of relevant securities | Nature of dealings | Purchase / Sale | Total number of shares involved | Total amount paid / received | Highest (H) prices paid / received | Lowest (L) prices paid / received |
|--------------------------------|------------------|---|--|-----------------|---------------------------------|------------------------------|------------------------------------|-----------------------------------|
| CICC Financial Trading Limited | 27 December 2024 | Other types of securities (e.g. equity swaps) | Closing / flattening / unwinding of proprietary positions arising from unsolicited client-driven dealings. I confirm this was done no later than the close of the morning trading session on the trading day following the originating client-driven dealing | Purchase | 164,000 | \$3,909,513.5500 | \$23.8385 | \$23.8385 |
| | | Other types of securities (e.g. equity swaps) | Closing / flattening / unwinding of proprietary positions arising from unsolicited client-driven dealings. I confirm this was done no later than the close of the morning trading session on the trading day following the originating client-driven dealing | Sale | 164,000 | \$3,910,974.0000 | \$23.8474 | \$23.8474 |

End



Note:

CICC Financial Trading Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

CICC Financial Trading Limited is ultimately owned by China International Capital Corporation Limited.